Switched Memory B-cells as a Marker for Humoral Immune System Recovery in Patients With Secondary Antibody Deficiency Due to Hematological Malignancies

NCT05612607 · clinicaltrials.gov ↗

PHASE4

Phase

UNKNOWN

Status

100

Enrollment

OTHER

Sponsor class

Conditions

Secondary Antibody Deficiency

Interventions

DRUG: Immunoglobulin replacement therapy (IGRT)

Sponsor

Ottawa Hospital Research Institute